Periodontal Disease Therapeutics Market Size, Share, Trends, Business development, Analysis And Opportunities 2018 - 2026
Periodontal Disease Therapeutics Market |
Periodontal therapies are products that are used to treat periodontitis. Periodontitis is a bacterial infection that develops over time as a result of microbial plaque, also known as gum disease, colonising the tooth surface and below the gingival margin. Hormonal changes, smoking, poor dental hygiene, and some inherited factors all contribute to periodontal disease. Periodontal disease is characterised by the progressive loss of alveolar bone and is most commonly seen in adults.
Adults are the most common victims of periodontal disease. According to the Centers for Disease Control and Prevention (CDC), the prevalence of periodontitis in persons aged 30 and older in the United States was predicted to be over 50% in 2018, resulting in 64.7 million Americans. 8.7% of the individuals had mild periodontitis, 30% had intermediate periodontitis, and 8.5 percent had severe chronic periodontitis. The frequency of the disease rises with age, with periodontitis affecting 70% of persons aged 65 and more. Many environmental risk factors are linked to inflammatory responses, such as smoking, diabetes, and bad health behaviours, which drive the chronic inflammatory response in periodontitis and are advantageous to the Periodontal Disease Therapeutic Market.
Market Segmentation:
By Drug Type
- Arestin
- Atridox
- Doxycycline
- Metronidazole
- Minocycline
- Periochip
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Channel
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
The key players in operating in the periodontal disease therapeutic market include DenMat Holdings LLC., 3M, Valeant Pharmaceuticals International, Inc., Galderma S.A., Dexcel Pharma Ltd., Kaken Pharmaceutical Co., Ltd., and OraPharma Inc.
Comments
Post a Comment